Showing results (61-70 of 93) with videos related to

Sort By:
Pageof 10
Carcinogenesis|May 28, 2020
3,3-Diindolylmethane (DIM): a nutritional intervention and its impact on breast density in healthy BRCA carriers. A prospective clinical trialRinat Yerushalmi, Sharon Bargil, Yaara Ber, et al.
Journal of Surgical Oncology|May 18, 2006
Preoperative chemoradiation in rectal cancer: Retrospective comparison between capecitabine and continuous infusion of 5-fluorouracilRinat Yerushalmi, Efraim Idelevich, Ygael Dror, et al.
International Journal of Clinical Practice|December 30, 2016
Perception of prognosis of cancer patients by non-oncologistsHadar Goldvaser, Yonatan Milman, Tal Dujovni, et al.
Clinical Breast Cancer|August 8, 2009
A phase II trial of a neoadjuvant platinum regimen for locally advanced breast cancer: pathologic response, long-term follow-up, and correlation with biomarkersRinat Yerushalmi, Malcolm M Hayes, Karen A Gelmon, et al.
Clinical Imaging|November 10, 2020
Timing to imaging and surgery after neoadjuvant therapy for breast cancerAhuva Grubstein, Yael Rapson, Salomon M Stemmer, et al.
Breast Cancer Research and Treatment|April 8, 2022
Rate of breast biopsy referrals in female BRCA mutation carriers aged 50 years or more: a retrospective comparative study and matched analysisAdi Pomerantz, Daliah Tsoref, Ahuva Grubstein, et al.
Plos One|July 23, 2013
Phase II study of concurrent capecitabine and external beam radiotherapy for pain control of bone metastases of breast cancer originYulia Kundel, Nicola J Nasser, Ofer Purim, et al.
Oncotarget|April 18, 2018
Premature ovarian aging in BRCA carriers: a prototype of systemic precocious aging?Irit Ben-Aharon, Mattan Levi, David Margel, et al.
The Lancet. Oncology|August 25, 2011
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised studyKaren A Gelmon, Marc Tischkowitz, Helen Mackay, et al.
Breast Cancer Research and Treatment|April 3, 2024
BRCA1/2 mutation carriers vs the general breast cancer population (N = 799,986): 21-gene assay-based molecular characterizationRinat Yerushalmi, Adi Pomerantz, Ron Lewin, et al.
Pageof 10